Your browser doesn't support javascript.
loading
EROS 2.0 study: evaluation of two interventional radiotherapy (brachytherapy) schedules for endometrial cancer: a comparison of late vaginal toxicity rates.
Lancellotta, Valentina; Macchia, Gabriella; Dinapoli, Nicola; Autorino, Rosa; Campitelli, Maura; Nardangeli, Alessia; Salvati, Alessandra; Fionda, Bruno; Casà, Calogero; Cornacchione, Patrizia; Rovirosa, Angeles; Kovács, György; Morganti, Alessio Giuseppe; Ferrandina, Maria Gabriella; Gambacorta, Maria Antonietta; Tagliaferri, Luca.
Afiliação
  • Lancellotta V; UOC Radioterapia Oncologica, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, 00128, Rome, Italy.
  • Macchia G; Gemelli Molise Hospital, Radiation Oncology Unit, Università Cattolica del Sacro Cuore, 86100, Campobasso, Italy. macchiagabriella@gmail.com.
  • Dinapoli N; UOC Radioterapia Oncologica, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, 00128, Rome, Italy.
  • Autorino R; UOC Radioterapia Oncologica, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, 00128, Rome, Italy.
  • Campitelli M; UOC Radioterapia Oncologica, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, 00128, Rome, Italy.
  • Nardangeli A; UOC Radioterapia Oncologica, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, 00128, Rome, Italy.
  • Salvati A; UOC Radioterapia Oncologica, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, 00128, Rome, Italy.
  • Fionda B; UOC Radioterapia Oncologica, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, 00128, Rome, Italy.
  • Casà C; UOC Radioterapia Oncologica, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, 00128, Rome, Italy.
  • Cornacchione P; UOC Radioterapia Oncologica, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, 00128, Rome, Italy.
  • Rovirosa A; Department of Radiation Oncology, Hospital Clinic i Universitari, Fonaments Clinics Department, University of Barcelona, 08036, Barcelona, Spain.
  • Kovács G; Università Cattolica del Sacro Cuore, 00128, Roma, Italy.
  • Morganti AG; Radiotherapy Center, IRCCS Azienda Ospedaliera Universitaria di Bologna, 40138, Bologna, Italy.
  • Ferrandina MG; DIMES, Alma Mater Studiorum University of Bologna, 40138, Bologna, Italy.
  • Gambacorta MA; Woman, Child and Public Health Department, Fondazione Policlinico Universitario "A. Gemelli", IRCCS, Roma, Italy.
  • Tagliaferri L; UOC Radioterapia Oncologica, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, 00128, Rome, Italy.
Radiol Med ; 127(3): 341-348, 2022 Mar.
Article em En | MEDLINE | ID: mdl-35092552
ABSTRACT

BACKGROUND:

To compare the late toxicity rates after two different high dose rate (HDR) adjuvant intravaginal interventional radiotherapy (IRT-brachytherapy) dose schedules in stage I-II endometrial cancer.

METHODS:

Stage I-II patients with endometrial cancer treated with surgery (with or without lymphadenectomy) and adjuvant HDR-IRT between 2014 and 2020 were included in this analysis. Patients were treated with two schedules. In the first cohort (C1), 21 Gy were delivered in three weekly fractions (7 Gy) prescribed 0.5 cm from the applicator surface. In the second cohort (C2), 24 Gy were delivered in four weekly fractions (6 Gy). The clinical target volume was the upper third of the vagina for C1 and the upper 3 cm for C2. HDR-IRT technique and point prescription (5 mm depth from the applicator surface) were the same for all patients. Vaginal toxicity was scored according to the CTCAE 5.0 scale in terms of the presence versus absence of any toxicity grade. The correlation among toxicity and clinical covariates (age, lymphadenectomy, fractionation, stage) was tested by Pearson correlation test (univariate) and by logistic regression (multivariable).

RESULTS:

114 stage I and three stage II patients, median age 62 (range 32-85) years, were included in this analysis. The mean follow-up was 56.3 months in C1 (40-76) and 20 months in C2 (8-42). Vaginal late toxicity was recorded in 40 and 15 patients in C1 and 2, respectively. Age, lymphadenectomy, and fractionation were significantly correlated with toxicity at univariate analysis (p value = 0.029, 0.006, and 0.002, respectively), while stepwise logistic regression confirmed only age and fractionation as significantly correlated parameters (p value = 0.02 and 0.001, respectively). Three-year local relapse-free, distant metastasis-free and cause-specific survival rates were 96.6%, 94.8%, and 99.1%, respectively.

CONCLUSIONS:

This analysis showed lower vaginal late toxicity rate in C2 compared to C1.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Braquiterapia / Neoplasias do Endométrio Limite: Female / Humans / Middle aged Idioma: En Revista: Radiol Med Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Itália

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Braquiterapia / Neoplasias do Endométrio Limite: Female / Humans / Middle aged Idioma: En Revista: Radiol Med Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Itália